| Patent application number | Description | Published |
|---|
| 20090018093 | Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics - The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE. | 01-15-2009 |
| 20090053138 | Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics - Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto. | 02-26-2009 |
| 20090082555 | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics - The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics. | 03-26-2009 |
| 20090105172 | Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics - The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands. | 04-23-2009 |
| 20090149643 | Aptamers to von Willebrand factor and their use as thrombotic disease therapeutics - The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to von Willebrand Factor. | 06-11-2009 |
| 20090221680 | Aptamers that bind thrombin with high affinity - The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin. | 09-03-2009 |
| 20100120024 | Materials and methods for the generation of transcripts comprising modified nucleotides - Materials and Methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence. | 05-13-2010 |
| 20110098345 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics - The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI. | 04-28-2011 |
